Advertisement

Introduction to the Second Edition of the Bethesda System for Reporting Thyroid Cytopathology

  • Marc PusztaszeriEmail author
Chapter

Abstract

The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) is an evidence-based standardized reporting system for thyroid fine-needle aspiration (FNA) specimens, with six diagnostic categories that are associated with an implied risk of malignancy and clinical management scenario(s). Since its implementation in 2009, TBSRTC has been widely adopted internationally and has contributed significantly to the management of patients with thyroid nodules by increasing the quality and reproducibility of thyroid cytology reporting. As a result, considerable experience has been gained worldwide regarding its application to cytology practice, clinical impact, and limitations. In addition, several new developments have emerged in the field of thyroid pathology in recent years. These include (1) the revised ATA guidelines for the management of patients with thyroid nodules, in which risk stratification by clinical/radiological/pathological features and more conservative management are emphasized; (2) the widespread use of molecular testing of thyroid FNA samples, which has transformed the management of patients with thyroid nodules, especially in the United States; and (3) the reclassification of the encapsulated follicular variant of papillary thyroid carcinoma as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) as an attempt to reduce overdiagnosis and overtreatment of patients with this low-risk thyroid neoplasm. In light of these important advances in the management of patients with thyroid nodules and in thyroid carcinogenesis, it was an appropriate time for updating TBSRTC, and a thoroughly revised and updated second edition of the Atlas (TBSRTC 2) was published in October 2017. In this chapter, we introduce TBSRTC 2, focusing on the major changes and updates.

Keywords

Thyroid Cytopathology Fine-needle aspiration Terminology Bethesda Noninvasive follicular thyroid neoplasm with papillary-like nuclear features NIFTP Molecular testing 

References

  1. 1.
    Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute thyroid fine needle aspiration state of the science conference: a summation. Cytojournal. 2008;5:6.CrossRefGoogle Scholar
  2. 2.
    Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36:425–37.CrossRefGoogle Scholar
  3. 3.
    Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology: definitions, criteria and explanatory notes. New York, NY: Springer; 2009.Google Scholar
  4. 4.
  5. 5.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefGoogle Scholar
  6. 6.
    Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9.CrossRefGoogle Scholar
  7. 7.
    Ali SZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology: definitions, criteria and explanatory notes. New York, NY: Springer; 2018.CrossRefGoogle Scholar
  8. 8.
    Pusztaszeri M, Rossi ED, Auger M, et al. The Bethesda system for reporting thyroid cytopathology: proposed modifications and updates for the second edition from an international panel. Acta Cytol. 2016;60:399–405.CrossRefGoogle Scholar
  9. 9.
    Pusztaszeri M, Rossi ED, Auger M, et al. The Bethesda system for reporting thyroid cytopathology: proposed modifications and updates for the second edition from an international panel. JASC. 2016;5:245–51.PubMedGoogle Scholar
  10. 10.
    Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 2012;56:333–9.CrossRefGoogle Scholar
  11. 11.
    Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015;25:987–92.CrossRefGoogle Scholar
  12. 12.
    Faquin WC, Wong LQ, Afrogheh AH, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in the Bethesda system for reporting thyroid cytopathology. Cancer Cytopathol. 2016;124:181–7.CrossRefGoogle Scholar
  13. 13.
    Iskandar ME, Bonomo G, Avadhani V, Persky M, Lucido D, Wang B, Marti JL. Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III. Surgery. 2015;157:510–7.CrossRefGoogle Scholar
  14. 14.
    Kakudo K, Higuchi M, Hirokawa M, Satoh S, Jung CK, Bychkov A. Thyroid FNA cytology in Asian practice-active surveillance for indeterminate thyroid nodules reduces overtreatment of thyroid carcinomas. Cytopathology. 2017;28:455–66.CrossRefGoogle Scholar
  15. 15.
    Krane JF, Alexander EK, Cibas ES, Barletta JA. Coming to terms with NIFTP: a provisional approach for cytologists. Cancer Cytopathol. 2016;124:767–72.CrossRefGoogle Scholar
  16. 16.
    Renshaw AA. Histologic follow-up of nondiagnostic thyroid fine needle aspirations: implications for adequacy criteria. Diagn Cytopathol. 2012;40:E13–5.CrossRefGoogle Scholar
  17. 17.
    Vivero M, Renshaw AA, Krane JF. Adequacy criteria for thyroid FNA evaluated by ThinPrep slides only. Cancer. 2017;125:534–43.Google Scholar
  18. 18.
    Singh RS, Wang HH. Timing of repeat thyroid fine needle aspiration in the management of thyroid nodules. Acta Cytol. 2011;55:544–8.CrossRefGoogle Scholar
  19. 19.
    Lee HY, Baek JH, Yoo H, et al. Repeat fine-needle aspiration biopsy within a short interval does not increase the atypical cytologic results for thyroid nodules with previously nondiagnostic results. Acta Cytol. 2014;58:330–4.CrossRefGoogle Scholar
  20. 20.
    Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. Thyroid. 2011;11:271–7.CrossRefGoogle Scholar
  21. 21.
    Olson MT, Clark DP, Erozan YS, et al. Spectrum of risk of malignancy in subcategories of “atypia of undetermined significance”. Acta Cytol. 2011;55:518–25.CrossRefGoogle Scholar
  22. 22.
    VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011;136:572–7.CrossRefGoogle Scholar
  23. 23.
    Renshaw AA. Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy. Cancer Cytopathol. 2011;119:322–7.CrossRefGoogle Scholar
  24. 24.
    Krane JF, VanderLaan PA, Faquin WC, Renshaw AA. The AUS:M ratio: a proposed performance measure for reporting in the Bethesda system for thyroid cytopathology. Cancer Cytopathol. 2012;120:111–6.CrossRefGoogle Scholar
  25. 25.
    Roh MH, Jo VY, Stelow EB, et al. The predictive value of the fine needle aspiration diagnosis “Suspicious for a Follicular Neoplasm, Hürthle Cell Type” in patients with Hashimoto’s thyroiditis. Am J Clin Pathol. 2011;135:139–45.CrossRefGoogle Scholar
  26. 26.
    Brauner E, Holmes BJ, Krane JF, et al. Performance of the afirma gene expression classifier in Hürthle cell thyroid nodules differs from other indeterminate thyroid nodules. Thyroid. 2015;25:789–96.CrossRefGoogle Scholar
  27. 27.
    Pusztaszeri M, Auger M. Update on the cytologic features of papillary thyroid carcinoma variants. Diagn Cytopathol. 2017;45:714–30.CrossRefGoogle Scholar
  28. 28.
    Maletta F, Massa F, Torregrossa L, et al. Cytological features of “non-invasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology. Hum Pathol. 2016;54:134–42.CrossRefGoogle Scholar
  29. 29.
    Strickland K, Vivero M, Jo VY, et al. Pre-operative cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a prospective analysis. Thyroid. 2016;26:1466–71.CrossRefGoogle Scholar
  30. 30.
    Howitt BE, Chang S, Eszlinger M, et al. Fine-needle aspiration diagnoses of noninvasive follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2015;144:850–7.CrossRefGoogle Scholar
  31. 31.
    Tseng FY, Hsiao YL, Chang TC. Ultrasound-guided fine needle aspiration cytology of parathyroid lesions. A review of 72 cases. Acta Cytol. 2002;46:1029–36.CrossRefGoogle Scholar
  32. 32.
    Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, et al. Mammary analog secretory carcinoma of the thyroid gland: a primary thyroid adenocarcinoma harboring ETUG-NTRK3 fusion. Mod Pathol. 2016;29:985–95.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of PathologyJewish General Hospital and McGill UniversityMontrealCanada

Personalised recommendations